American journal of hematology
- Label
- American journal of hematology (literal)
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
- 14q32/miRNA clusters loss of heterozygosity in acute lymphoblastic leukemia is associated with up-regulation of BCL11a. (Articolo in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1101)
- Differential expression of specific microRNA and their targets in acute myeloid leukemia (Articolo in rivista) (Prodotto della ricerca)
- Plasma chitotriosidase activity in patients with beta-thalassemia. (Articolo in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1101)
- Differentiating germinal center-derived lymphomas through their cellular microenvironment (Articolo in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1101)
- Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia (Articolo in rivista) (Prodotto della ricerca)
- Alternative label
- Am. j. hematol. (literal)
- AJH (literal)
- American journal of hematology. (literal)
- Language
- eng (literal)
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#issn
- 0361-8609 (literal)
- Preferred label
- American journal of hematology (literal)
- Publisher
- Wiley-Liss, Inc. Hoboken, N.J., USA (literal)
Incoming links:
- Rivista
- Differential expression of specific microRNA and their targets in acute myeloid leukemia (Articolo in rivista) (Prodotto della ricerca)
- 14q32/miRNA clusters loss of heterozygosity in acute lymphoblastic leukemia is associated with up-regulation of BCL11a. (Articolo in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1101)
- Plasma chitotriosidase activity in patients with beta-thalassemia. (Articolo in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1101)
- Differentiating germinal center-derived lymphomas through their cellular microenvironment (Articolo in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1101)
- Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia (Articolo in rivista) (Prodotto della ricerca)
